Ensysce Biosciences (ENSC) Minority Interest (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Minority Interest of -$328970.0 for Q4 2025, little changed year-over-year from -$329458.4 in Q4 2024, and little changed quarter-over-quarter from -$328649.0 in Q3 2025.
Ensysce Biosciences (ENSC) Minority Interest (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Minority Interest for 6 consecutive years, with -$328970.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Minority Interest changed 0.15% year-over-year to -$328970.0; the TTM figure through Dec 2025 stood at -$328970.0 (changed 0.15% YoY), while the FY2025 annual figure was -$328970.0, changed 0.15% from the prior year.
- Minority Interest was little changed at -$328970.0 in Q4 2025 per ENSC's latest filing, from -$328649.0 in the prior quarter.
- Across five years, Minority Interest topped out at -$243653.0 in Q2 2021 and bottomed at -$328970.0 in Q4 2025.
- Historically, Minority Interest has averaged -$313746.3 across 5 years, with a median of -$327444.0 in 2023.
- Annual changes were most pronounced in 2021 — Minority Interest dropped 28.58% — and 2025, when it changed 0.0%.
- Ensysce Biosciences' Minority Interest stood at -$279815.0 in 2021, then declined by 12.65% to -$315208.0 in 2022, then dropped by 4.19% to -$328409.0 in 2023, then declined by 0.02% to -$328483.0 in 2024, then dropped by 0.15% to -$328970.0 in 2025.
- Business Quant data shows ENSC's Minority Interest at -$328970.0 in Q4 2025, -$328649.0 in Q3 2025, and -$328649.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -328,970.00 |
| Sep 30, 2025 | -328,649.00 |
| Jun 30, 2025 | -328,649.00 |
| Mar 31, 2025 | -328,483.00 |
| Dec 31, 2024 | -328,483.00 |
| Sep 30, 2024 | -328,483.00 |
| Jun 30, 2024 | -328,483.00 |
| Mar 31, 2024 | -328,483.00 |
| Dec 31, 2023 | -328,409.00 |
| Sep 30, 2023 | -327,444.00 |
| Jun 30, 2023 | -326,209.00 |
| Mar 31, 2023 | -319,149.00 |
| Dec 31, 2022 | -315,208.00 |
| Sep 30, 2022 | -327,434.00 |
| Jun 30, 2022 | -305,942.00 |
| Mar 31, 2022 | -279,633.00 |
| Dec 31, 2021 | -279,815.00 |
| Sep 30, 2021 | -279,601.00 |
| Jun 30, 2021 | -243,653.00 |
| Dec 31, 2020 | -217,625.00 |